ArticleNeuroscience applied2026
A national approach in a European context: Multidisciplinary and multiprofessional recommendations on the clinical use of psychedelic substances.
Article in Neuroscience applied, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic benefits of psychedelics for neuropsychiatric conditions have gathered significant attention in Europe and around the world, with treatments using psilocybin, MDMA, and ketamine as notable examples. However, the mind-altering effects of these substances, and the complexity of their regulatory frameworks, both within and outside of therapeutic use, imply careful clinical guidance. Across Europe, associations dedicated to therapeutic use of psychedelics are flourishing, and have produced clinical recommendations, while more generalist professional boards have contributed with various clinical reports, statements and guidelines. In Portugal this prompted a unique collaborative movement of professional associations of Pharmacists, Psychologists and Physicians to work with national ethics authorities, scientific societies and both research and clinical stakeholders, to produce a consensual recommendation addressing core aspects of psychedelic treatments. This statement reflects positions regarding informed consent, the determinants of medical and psychological interventions, ethical considerations and regulatory recommendations. The initial document was open for public consultation, inviting other stakeholders to contribute to the final version, published in Portuguese and translated here into English towards broader access. The statement underscores the importance of multidisciplinary and multiprofessional collaboration among psychiatrists, psychologists and pharmacists, towards establishing common guidelines and regulations to ensure safe and effective clinical applications. By addressing these factors, the recommendations aim to foster responsible therapeutic use, while safeguarding patient well-being.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.